Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 19 years or older with healthy ocular status and pre-operative refractive anisometropia of less than 2.000 diopters between eyes undergoing bilateral PRK surgery.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Those desiring PRK in only one eye, those in need of additional topical eye medications, those with history of drug/alcohol abuse, women breastfeeding or pregnant.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nevanac (Type: EXPERIMENTAL): One drop, three times daily, in the assigned eye for the first three postoperative days
- Acular LS (Type: PLACEBO_COMPARATOR): One drop, three times daily, in the assigned eye for the first three postoperative days

Based on this trial design, predict the completion outcome and termination type (if applicable).